Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naotai Fang is a Traditional Chinese Medicine (TCM) herbal formula developed by researchers at the Hu'nan University of Chinese Medicine for the treatment of cerebrovascular diseases, particularly hypertensive cerebral small vessel disease (CSVD) and ischemic stroke. The formula typically comprises four medicinal components: *Astragalus membranaceus* (Huangqi), *Scolopendra subspinipes* (Centipede), *Hirudo nipponica* (Leech), and *Rheum palmatum* (Rhubarb). Its pharmacological actions include neuroprotection, anti-inflammatory effects, and the promotion of angiogenesis. In clinical and preclinical studies, Naotai Fang has demonstrated the ability to improve cognitive function, reduce blood-brain barrier permeability, and modulate pathways related to apoptosis and oxidative stress. It is currently being evaluated in multi-center clinical trials to standardize its use in integrated traditional Chinese and Western medicine protocols.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naotai fang.